Vertex Expands Portfolio With $10B Purchase of Crinetics

WHO:

STAT - Vertex Pharmaceuticals and Crinetics Pharmaceuticals are the companies involved in the acquisition.

WHAT:

STAT - Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion.

STAT - The acquisition price amounts to roughly $85 per share of Crinetics’ stock.

Endpoints News - This acquisition is the largest in Vertex's history.

STAT - Crinetics’ commercial drug, Palsonify, treats a rare endocrine disorder called acromegaly.

STAT - Crinetics is also developing a therapy for congenital adrenal hyperplasia.

WHERE:

STAT - The companies are based in the biotechnology sector, though specific locations are not mentioned.

WHEN:

STAT - The acquisition was announced on a Monday, though the specific date is not provided.

STAT - Palsonify was launched last year.

WHY:

Endpoints News - The acquisition aims to beef up Vertex's commercial portfolio.

HOW:

STAT - The deal involves Vertex purchasing Crinetics Pharmaceuticals and its drug candidates.

(UPDATED July 7, 2026 17:46 UTC)

Vertex Pharmaceuticals has announced it will acquire Crinetics Pharmaceuticals for a staggering $10 billion, marking the largest acquisition in Vertex's history. The deal, which values Crinetics’ stock at approximately $85 per share, includes Crinetics' commercial drug Palsonify, used to treat the rare endocrine disorder acromegaly, as well as its ongoing development of a therapy for congenital adrenal hyperplasia. This strategic move is designed to enhance Vertex's commercial portfolio in the biotechnology sector.